Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rhBMP-2/CPM · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | 1.0 mg/mL rhBMP-2/CPM + SOC |
| B | EXPERIMENTAL | 2.0 mg/mL rhBMP-2/CPM + SOC |
| C | ACTIVE_COMPARATOR | Buffer/CPM + SOC |
| D | OTHER | Standard of Care Alone (SOC) |
| Name | Type | Description |
|---|---|---|
| rhBMP-2/CPM | DRUG | - |
| surgical intervention alone | OTHER | surgical internal fixation of fracture defines the standard of care group |
Inclusion Criteria: * Skeletally mature subjects age 18 years or older. * Subjects with either a closed proximal humeral fracture or a diaphyseal humeral fracture. * Treatment plan that includes only conservative (nonoperative) therapy within 48 hours following injury. Exclusion Criteria: * Shoul...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 23 | N/A | Undisclosed |
| Stryker Corporation | SYK | 4 | - | Undisclosed |
| Johnson & Johnson | JNJ | 1 | N/A | Undisclosed |
| Orthofix Medical, Inc. | OFIX | 1 | - | Undisclosed |
| Cooper Companies, Inc. | COO | 1 | - | Undisclosed |
rhBMP-2/CPM is an investigational small molecule being developed for musculoskeletal conditions, including osteoarthritis, radius fractures, and other fractures. It has been studied in clinical trials for closed distal radius fractures, open wedge osteotomies, hip fractures, and closed fractures of the humerus.
Pfizer, Inc. (NYSE: PFE) is developing rhBMP-2/CPM. The drug is currently in Phase 2 clinical development for musculoskeletal indications.
rhBMP-2/CPM is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, along with two earlier-phase studies.
rhBMP-2/CPM has been studied in four completed trials. NCT00161629 evaluated it in closed distal radius fractures, NCT00243295 in open wedge osteotomies, NCT00384358 in hip fractures, and NCT00384852 in closed fractures of the humerus. Total enrollment across these studies was 247 participants.
rhBMP-2/CPM is the drug name used in most trials. One trial, NCT00243295, refers to the drug as rhMBP-2/CPM, which appears to be a typographical variant of the same compound. Both names refer to the same investigational therapy.